Los Angeles Capital Management’s Adaptive Biotechnologies ADPT Stock Holding History

Los Angeles Capital Management’s Portfolio ADPT Stock Details ADPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$10.2K	Hold	474	–	–	﹤0.01%	1959
2026 Q1	$6.58K	Hold	474	–	–	﹤0.01%	2052
2025 Q4	$8.02K	Buy	+474	New	+$7.74K	﹤0.01%	2154
2025 Q1	–	Sell	-44,069	Closed	-$264K	–	1080
2024 Q4	$264K	Hold	44,069	–	–	﹤0.01%	974
2024 Q3	$226K	Sell	44,069 -90	-0.2%	-$392	﹤0.01%	1094
2024 Q2	$160K	Buy	44,159 +22,527	+104%	+$71.5K	﹤0.01%	1138
2024 Q1	$69.4K	Hold	21,632	–	–	﹤0.01%	1120
2023 Q4	$106K	Hold	21,632	–	–	﹤0.01%	1115
2023 Q3	$118K	Buy	21,632 +312	+1%	+$2.06K	﹤0.01%	1087
2023 Q2	$143K	Sell	21,320 -326	-2%	-$2.42K	﹤0.01%	1133
2023 Q1	$191K	Buy	21,646 +1,593	+8%	+$14K	﹤0.01%	1126
2022 Q4	$153K	Sell	20,053 -1,934	-9%	-$15K	﹤0.01%	1156
2022 Q3	$157K	Buy	+21,987	New	+$207K	﹤0.01%	1187

Other funds holding ADPT

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Los Angeles Capital Management's ADPT Position: Q2 2026 in Review

Los Angeles Capital Management held its Adaptive Biotechnologies (ADPT) position steady in Q2 2026 at 474 shares worth $10.2K. The position accounts for ﹤0.01% of the portfolio, ranked #1959.

Los Angeles Capital Management first reported a position in ADPT in Q3 2022 and has held it in 13 quarters since. The position peaked at $264K in Q4 2024. 300 funds tracked by Wall St. Rank hold ADPT as of Q2 2026.

Los Angeles Capital Management held 474 shares of Adaptive Biotechnologies worth $10.2K as of Q2 2026.
Los Angeles Capital Management left its Adaptive Biotechnologies share count unchanged in Q2 2026.
Adaptive Biotechnologies made up ﹤0.01% of Los Angeles Capital Management's portfolio in Q2 2026, its #1959 holding.
Los Angeles Capital Management first reported a position in Adaptive Biotechnologies in Q3 2022 and has held it in 13 quarters since.
Los Angeles Capital Management's Adaptive Biotechnologies position peaked at $264K in Q4 2024.
300 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q2 2026.

Based on Los Angeles Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.